Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies
Purpose of review: Global policy changes have increased access to products containing cannabidiol (CBD), a primary constituent of hemp and cannabis. The CBD product industry has experienced tremendous growth, in part, because CBD is widely touted as an effective therapeutic for myriad health conditions. However, only 1 CBD product (Epidiolex®) has been approved by the U.S. Food and Drug Administration (FDA) to date. There is substantial interest among consumers and the medical and scientific communities regarding the therapeutic potential of CBD, including for novel indications that are not recognized by the FDA. The purpose of this review was to synthesize available evidence from clinical research regarding the efficacy of CBD as a therapeutic.
Recent findings: Human laboratory studies and clinical trials (e.g., randomized controlled trials and single-arm, open label trials) evaluating the efficacy of CBD as a therapeutic were identified for various medical conditions, including epilepsy, anxiety, pain/inflammation, schizophrenia, various substance use disorders, post-traumatic stress disorder, and others. There is clear evidence supporting the utility of CBD to treat epilepsy. For other health conditions reviewed, evidence was often mixed and/or there was a general lack of well-powered randomized, placebo-controlled studies to draw definitive conclusions.
Summary: Rigorous, controlled evidence for the therapeutic efficacy of CBD is lacking for many health conditions. Possible concerns with the use of CBD as a therapeutic include the potential for adverse effects (e.g., liver toxicity), drug-drug interactions, and lack of sufficient regulatory oversight of retail CBD products.
Keywords: cannabidiol; cannabinoids; cannabis; clinical trials.
Conflict of interest statement
Conflicts of interest: The authors declare no conflicts of interested in relation to this work.
Koturbash I, MacKay D. Koturbash I, et al. J Diet Suppl. 2020;17(5):487-492. doi: 10.1080/19390211.2020.1796886. Epub 2020 Jul 25. J Diet Suppl. 2020. PMID: 32715797
Britch SC, Babalonis S, Walsh SL. Britch SC, et al. Psychopharmacology (Berl). 2021 Jan;238(1):9-28. doi: 10.1007/s00213-020-05712-8. Epub 2020 Nov 21. Psychopharmacology (Berl). 2021. PMID: 33221931 Free PMC article. Review.
Gaston TE, Szaflarski JP. Gaston TE, et al. Curr Neurol Neurosci Rep. 2018 Sep 8;18(11):73. doi: 10.1007/s11910-018-0882-y. Curr Neurol Neurosci Rep. 2018. PMID: 30194563 Review.
Oberbarnscheidt T, Miller NS. Oberbarnscheidt T, et al. J Clin Med Res. 2020 Jul;12(7):393-403. doi: 10.14740/jocmr4159. Epub 2020 Jun 25. J Clin Med Res. 2020. PMID: 32655732 Free PMC article. Review.
O’Connell BK, Gloss D, Devinsky O. O’Connell BK, et al. Epilepsy Behav. 2017 May;70(Pt B):341-348. doi: 10.1016/j.yebeh.2016.11.012. Epub 2017 Feb 8. Epilepsy Behav. 2017. PMID: 28188044 Review.
Castelli V, Lavanco G, D’Amico C, Feo S, Tringali G, Kuchar M, Cannizzaro C, Brancato A. Castelli V, et al. Front Pharmacol. 2023 Jul 31;14:1237485. doi: 10.3389/fphar.2023.1237485. eCollection 2023. Front Pharmacol. 2023. PMID: 37583903 Free PMC article.
Perini M, Gaggiotti A, Pianezze S, Ziller L, Larcher R. Perini M, et al. Antioxidants (Basel). 2023 Jul 14;12(7):1421. doi: 10.3390/antiox12071421. Antioxidants (Basel). 2023. PMID: 37507959 Free PMC article.
Staben J, Koch M, Reid K, Muckerheide J, Gilman L, McGuinness F, Kiesser S, Oswald IWH, Koby KA, Martin TJ, Kaplan JS. Staben J, et al. Front Neurosci. 2023 Jun 16;17:1185737. doi: 10.3389/fnins.2023.1185737. eCollection 2023. Front Neurosci. 2023. PMID: 37397463 Free PMC article.
Shreiber-Livne I, Sulimani L, Shapira A, Procaccia S, Meiri D, Sosnik A. Shreiber-Livne I, et al. Drug Deliv Transl Res. 2023 Jun 21. doi: 10.1007/s13346-023-01380-1. Online ahead of print. Drug Deliv Transl Res. 2023. PMID: 37341881
Dammann I, Keil C, Hardewig I, Skrzydlewska E, Biernacki M, Haase H. Dammann I, et al. Nat Prod Bioprospect. 2023 Jun 7;13(1):19. doi: 10.1007/s13659-023-00382-3. Nat Prod Bioprospect. 2023. PMID: 37284961 Free PMC article.